Back to top

biotechnology: Archive

Zacks Equity Research

Bausch (BHC) Q4 Earnings and Revenues Top Estimates

Bausch (BHC) fourth-quarter earnings and sales beat their respective estimates. The guidance for 2024 looks encouraging.

PBYIPositive Net Change ADMANo Net Change EDITNegative Net Change BHCNegative Net Change

Zacks Equity Research

Why Apellis (APLS) Might Surprise This Earnings Season

Apellis (APLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

APLSPositive Net Change

Zacks Equity Research

Intra-Cellular (ITCI) Q4 Loss Narrower Than Expected, Sales Miss

Intra-Cellular (ITCI) reports mixed fourth-quarter 2023 results despite Caplyta sales rising year over year on the back of increasing prescription trends.

ACETPositive Net Change PBYIPositive Net Change ITCINegative Net Change ADMANo Net Change

Zacks Equity Research

Biotech Stock Roundup: MRNA's Q4 Results, RAPT Down on Study Results & Other Updates

Earnings from Moderna (MRNA) and pipeline update from RAPT are in focus in the biotech sector.

REGNPositive Net Change MRNANegative Net Change SRPTPositive Net Change IOVANegative Net Change RAPTNegative Net Change

Zacks Equity Research

CRISPR (CRSP) Q4 Earnings Top on Collaboration Revenues, Stock Up

CRISPR (CRSP) gains on encouraging fourth-quarter 2023 results, beating both earnings and revenue estimates on the back of collaboration revenues received from Vertex.

VRTXPositive Net Change PBYIPositive Net Change ADMANo Net Change CRSPNegative Net Change

Ekta Bagri

Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & More

Let us take a look at what's in store for biotech/drug stocks MRNA, BHC, NTLA, BMRN and ITCI, which are scheduled to report on Feb 22.

BMRNPositive Net Change MRNANegative Net Change ITCINegative Net Change NTLANegative Net Change BHCNegative Net Change

Zacks Equity Research

Bristol Myers' (BMY) Krazati sNDA for CRC Gets Priority Review

Bristol Myers (BMY) announces FDA's acceptance of the sNDA seeking approval for the Krazati/Erbitux combo therapy to treat CRC patients. A final decision is expected on Jun 21, 2024.

BMYPositive Net Change ACETPositive Net Change PBYIPositive Net Change ADMANo Net Change

Zacks Equity Research

Amphastar (AMPH) to Report Q4 Earnings: What's in the Cards?

Amphastar's (AMPH) revenues in the fourth quarter of 2023 are expected to have been driven by the sales of its pharmaceutical products.

AMPHPositive Net Change MRNANegative Net Change SRPTPositive Net Change CRSPNegative Net Change

Zacks Equity Research

BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards?

BeiGene's (BGNE) revenues in fourth-quarter 2023 are expected to have been driven by the sales of its marketed pharmaceutical products.

AMGNPositive Net Change SRPTPositive Net Change BGNEPositive Net Change CRSPNegative Net Change

Zacks Equity Research

Bayer (BAYRY) Intends to Slash Dividends Amid Challenges

Bayer (BAYRY) announced plans to cut dividends to pay out only the legally required minimum for three years in the wake of high debt and increasing legal costs.

BAYRYNegative Net Change SRPTPositive Net Change PBYIPositive Net Change EDITNegative Net Change

Zacks Equity Research

Roche's (RHHBY) Xolair Gets Approval for Food Allergies

Roche (RHHBY) obtains FDA approval for Xolair for the treatment of children and adults with one or more food allergies.

REGNPositive Net Change NVSPositive Net Change RHHBYPositive Net Change PBYIPositive Net Change

Zacks Equity Research

Sarepta's (SRPT) DMD Drug sBLA Gets FDA's Priority Tag, Stock Up

Sarepta (SRPT) announces the FDA's acceptance of its efficacy supplement to the Elevidys BLA, seeking to expand the treatment label for its DMD drug. The stock gains 8%.

RHHBYPositive Net Change SRPTPositive Net Change ADMANo Net Change IMCRPositive Net Change

Zacks Equity Research

Prothena (PRTA) Q4 Earnings Miss Estimates on Higher R&D Expense

Prothena (PRTA) posts a wider-than-expected loss in the fourth quarter on lower revenues and higher costs.

RHHBYPositive Net Change BMYPositive Net Change NVONegative Net Change PRTAPositive Net Change

Zacks Equity Research

Corcept (CORT) Q4 Earnings Beat Estimates, Korlym Sales Grow

Corcept (CORT) beats on both earnings and sales in the fourth quarter. The company also reiterates its previously provided guidance for 2024.

MRKPositive Net Change SRPTPositive Net Change CORTNegative Net Change PBYIPositive Net Change

Zacks Equity Research

Alnylam (ALNY) Q4 Loss Narrower Than Expected, Stock Dips 10%

Alnylam (ALNY) reports mixed fourth-quarter 2023 results, as earnings beat estimates, while revenues miss the same. The stock of the company falls 10%.

REGNPositive Net Change ALNYNegative Net Change NVSPositive Net Change RHHBYPositive Net Change

Zacks Equity Research

Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat

Ultragenyx (RARE) reports better-than-expected fourth-quarter 2023 results, beating both earnings and revenue estimates, driven by strong sales trends of Crysvita and Dojolvi.

REGNPositive Net Change PBYIPositive Net Change RAREPositive Net Change MREOPositive Net Change

Zacks Equity Research

New Strong Buy Stocks for February 16th

CDNS, ECL, FMX, KRRO and RMR have been added to the Zacks Rank #1 (Strong Buy) List on February 16, 2024.

ECLPositive Net Change FMXNegative Net Change CDNSNegative Net Change RMRPositive Net Change KRRONegative Net Change

Zacks Equity Research

C4 Therapeutics (CCCC) to Report Q4 Earnings: What's in Store?

When C4 Therapeutics, Inc. (CCCC), a clinical-stage biopharmaceutical company, reports fourth-quarter results, the focus will primarily be on pipeline progress.

IONSPositive Net Change NTLANegative Net Change RCUSNegative Net Change CCCCPositive Net Change

Zacks Equity Research

Biotech Stock Roundup: BIIB's Q4 Results, CBAY Up on GILD's Acquisition & Other Updates

Earnings from Biogen (BIIB) and CymaBay (CBAY) are in focus in the biotech sector.

BIIBPositive Net Change GILDPositive Net Change VRTXPositive Net Change CBAYPositive Net Change CRSPNegative Net Change

Zacks Equity Research

Exact Sciences (EXAS) to Post Q4 Earnings: What's in Store?

Exact Sciences' (EXAS) revenues in the fourth quarter of 2023 are likely to have been driven by its flagship cancer screening tests, Cologuard and Oncotype DX.

BMRNPositive Net Change MRNANegative Net Change EXASNegative Net Change NTLANegative Net Change

Zacks Equity Research

Drug, Biotech Stock Q4 Earnings Due on Feb 15: ALNY, BPMC & More

Let's look at five biotech/drug companies, ALNY, BPMC, AGIO, CORT and RARE, slated to release quarterly results on Feb 15.

ALNYNegative Net Change CORTNegative Net Change AGIOPositive Net Change RAREPositive Net Change BPMCPositive Net Change